https://ojs.bbwpublisher.com/index.php/IJGPN <p><em>International Journal of General Practice Nursing</em> (IJGPN) is an international, peer reviewed and open access journal that seeks to promote the development of nursing career. Articles which reflect the dynamics of nursing science and technology, summarize the progress of nursing scientific research, report new nursing knowledge and new technologies, display nursing scientific research achievements and advanced experience are encouraged to be submitted as original article, review, case report, short communication and letters. The covered topics include, but are not limited to: decision making, reviews, monographs and reviews in nursing, clinical research, nursing management, survey research, nursing education, health education, community nursing, case nursing, etc.</p> Bio-Byword Scientific Publishing Pty. Ltd. en-US International Journal of General Practice Nursing 2981-9415 https://ojs.bbwpublisher.com/index.php/IJGPN/article/view/12641 <p><em>Background</em>: Gout remains a challenging condition with rising global prevalence. The IL-1β drives disease pathogenesis, and high-sensitivity C-reactive protein (hsCRP) correlates with gout activity. Firsekibart, a novel fully human anti-IL-1β monoclonal antibody, has proven its efficacy on gout, while the data on reducing hsCRP remains limited. <em>Methods</em>: This multicenter, randomized, double-blind phase III trial compared Firsekibart (200 mg subcutaneous) with compound betamethasone (7 mg intramuscular) in acute gout patients who were contraindicated to, intolerant of, or unresponsive to NSAIDs and/or colchicine. Serum hsCRP levels were measured at 72 hours, 7 days post-dose, and 4 weeks post-dose. <em>Results</em>: Both groups achieved comparable hsCRP reduction at 72 hours (Firsekibart: −14.68 mg/L [95% CI: −15.75, −13.61] vs. compound betamethasone: −14.58 mg/L [−15.66, −13.50]; <em>P</em>=0.898). Firsekibart demonstrated better sustained suppression at 7 days post-dose (−18.63 vs. −9.28 mg/L, <em>P</em>&lt;0.001) and 4 weeks (−18.37 vs. −12.65 mg/L, <em>P</em>&lt;0.0001). <em>Conclusion</em>: Compared with compound betamethasone, Firsekibart showed a longer-lasting anti-inflammatory effect on gout patients. This result may provide significant clinical value in the management of gout and its associated complications.</p> Yu Xue Yi Li Yuling Lian Fei Gu Chunxia Chen Qian Xu Copyright (c) 2025 Author(s) 2025-11-07 2025-11-07 3 4 11 18 10.26689/ijgpn.v3i4.12641